Companies - Research and Markets - RSS Feed

Merck KGaA: Pipeline, Products, Performance and Potential

press@researchandmarkets.com — Wed, 16 Sep 2009 14:27:51 GMT

With a tradition of over three hundred years, Merck KGaA is one of the oldest pharmaceutical and chemical companies in the world Merck has 192 companies in 60 countries, which employ over 30,000 personnel worldwide Merck has focused its corporate headquarters and research & development in Darmstadt,...

Who Owns You? The Corporate Gold Rush to Patent Your Genes

press@researchandmarkets.com — Fri, 13 Feb 2009 15:02:06 GMT

Surely you own your own genes, don't you? Think again Now that the race to map the human genome is over, another competition has ensued Biotech companies, universities, and research institutions, sensing a biological gold mine, have been engaged in a furious scramble to patent human genes Presently,...

Competitor Analysis: C5a-R Antagonists

press@researchandmarkets.com — Wed, 14 Jan 2009 12:08:50 GMT

The present Competitive Intelligence Report about Complement C5a & C5a Receptor Antagonists provides a competitor evaluation in the field of R&D projects of antagonists used to interfere with the interaction of complement C5a and its receptor for the treatment of inflammatory diseases as of January...

The Top Five Global Pharma Companies; Where they are Now and Where they heading?

press@researchandmarkets.com — Thu, 08 Jan 2009 16:15:21 GMT

A mini report identifying drivers and barriers to sustaining financial performance over the next 5 years for the top five global pharmaceutical companies -Johnson & Johnson, Pfizer, GSK, Novartis and Sanofi-Aventis This report presents the cases of the top five global pharma companies: J&J, Pfizer,...

Emerging Blockbusters: 2009's Most Promising Drugs and the Future of the Blockbuster Model

press@researchandmarkets.com — Wed, 07 Jan 2009 15:28:17 GMT

Introduction In 2007, 93 blockbuster drugs (drugs with more than $1 billion in annual sales) were on the market and generated more than $220 billion in revenue These high-value products are fundamental to the success and growth of the pharmaceutical industry and the number of blockbusters on the...

What to Do When the R&D Pipeline Runs Dry

press@researchandmarkets.com — Wed, 07 Jan 2009 10:42:56 GMT

The pharmaceutical industry has been coping with declining R&D productivity for more than two decades and is under significant pressure to improve its bottom line and growth prospects Industry stakeholders are seriously discussing whether companies should adopt new business models On the other hand,...

PharmaDeals®: Deal Making Spotlight on Sanofi-Aventis

press@researchandmarkets.com — Thu, 10 Jul 2008 08:42:41 GMT

One of a set of 5 reports detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, these reports are crucial to your deal making strategy Big pharma companies are often the partner of...

PharmaDeals®: Deal Making Spotlight on Pfizer

press@researchandmarkets.com — Thu, 10 Jul 2008 08:23:11 GMT

Directory of Clinical Research Companies in India

press@researchandmarkets.com — Wed, 27 Feb 2008 15:05:07 GMT

India is fast emerging as a favoured destination for clinical trials by global pharmaceutical and biotech companies that are looking for partnerships or setting up new operations Two major reasons for its popularity are: easy access and availability of a large, diverse and therapy-naïve population...

AstraZeneca: Pipeline, Products, Performance, Potential

press@researchandmarkets.com — Wed, 30 Jan 2008 14:23:17 GMT

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Executive Summary

On 6th April 1999, AstraZeneca was formed through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, propelling the company to second in the world in terms of pharmaceutical sales. Since the merger, AstraZeneca has maintained its position as one of the world's leading pharmaceutical companies having never left the top five companies in terms of pharmaceutical sales. Corporate headquarters are now based in London, UK; whilst R&D headquarters are in Sodertalje, Sweden.

Fiscal 2008 was a strong year for AstraZeneca, with growth recorded in revenue. This was achieved as a consequence of strong sales reported for AstraZeneca’s eleven key blockbuster products. Furthermore, AstraZeneca has invested over US$5 billion in R&D, in order to mitigate the major pipeline setbacks of fiscal 2006.
Firstly, in February 2006, AstraZeneca withdrew the recently-launched anticoagulant, Exanta, from the market. Due to poor patient safety data from clinical trials, which included an adverse-event report of serious liver injury. Not long afterwards, in May 2006, AstraZeneca discontinued its development programme for Galida, a treatment for glucose and lipid abnormalities associated with Type II diabetes. The company decided that t

MedImmune Inc.: PharmaVitae Profile

press@researchandmarkets.com — Tue, 18 Dec 2007 15:03:53 GMT

Introduction

This analysis examines the historical and forecast performance for MedImmune in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark MedImmunes performance against key rivals in the ethical pharmaceutical sector See how MedImmune will build on its Synagis success with the launch of follow-on product Numax, which is set to drive growth over the forecast period Following the acquisition of MedImmune by AstraZeneca, evaluate the contribution to the Anglo-Swedish company’s top-line figures from 2006 to 2012

Shire: Pipeline, Products, Performance and Potential

press@researchandmarkets.com — Tue, 27 Nov 2007 14:38:35 GMT

In the last five years, Shire has spent over US$8 billion on acquisitions which have seen the company considerably expand its global presence and areas of interest Most importantly, these acquisitions have added four key products to a portfolio that was becoming dated and facing threats to its...

Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff

press@researchandmarkets.com — Wed, 17 Oct 2007 08:31:48 GMT

Introduction This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company It identifies four established and four emerging players within the mAb sector which are forecast to play the most commercially significant role within this market The report assesses how...

Trends in the Commercialization of Biomarkers: Tests and Companies

press@researchandmarkets.com — Mon, 08 Oct 2007 13:59:39 GMT

As health care moves toward personalized medicine, biomarkers have gained an increasingly important role in the delivery of efficient, quality care The FDA has established specific definitions for biomarkers, and diagnostics, biotechnology, and pharmaceutical companies have woken up to biomarkers’...

Does the Treatment of Huntington's Disease Represent a Commercial Opportunity?

press@researchandmarkets.com — Thu, 06 Sep 2007 15:03:49 GMT

Huntington’s disease (HD) is a genetic neurological disorder characterized by uncontrolled body movements and cognitive dysfunction No drugs are approved to treat the disorder, leaving a high level of unmet need Commercial opportunity abounds, but the small patient population deters some companies...

E7: The Outlook for Pharmaceuticals to 2012

press@researchandmarkets.com — Fri, 31 Aug 2007 11:27:21 GMT

E7: The Outlook for Pharmaceuticals to 2012 is a new collection of management reports from Espicom Business Intelligence. Each report provides an individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually or as a discounted collection.

Executive Summary

7 Markets Covered!
Brazil, India, Mexico, Turkey,
China, Indonesia and Russia. Highlights from the report: BRAZIL
Due to the depreciation of the US dollar, the Brazilian pharmaceutical market is experiencing high growth in dollar values. The Brazilian pharmacy sector was valued at US$9.8 billion in 2006, ahead of the pharmacy sector in Mexico, valued at US$9.6 billion. Drug prices continue to increase in spite of generic competition. The generics sector is dominated by local producers, restricting the market entry for foreign producers. In 2006, generics sales amounted to US$1.1 billion, equal to 10.7% of the overall pharmacy sector. Generics sales will continue to outperform the pharmacy sector, fuelled by generics production of oral contraceptives & hormones and blockbusters losing their patents.

CHINA
The Chinese pharmaceutical market has shown impressive growth in recent years, in tandem with the country’s rapid economic expansion. The influx of foreign multinationals in recent years has offered continued investment, and production plants and R&D facilities are being expanded all the time. Improvements in regulatory practices are making the ability to sell imported products quicker and easier, while the lowering of tariffs on imported goods and an increase in transparency of legislation has made a notoriously hard-to-penetrate market a more attractive proposition for overseas companies. The market is heavily reliant on locally-produced generics or copy products. Intellectual property provision is theoretically strong; China be

Kyowa Hakko: Performance, Products, Pipeline and Potential

press@researchandmarkets.com — Wed, 01 Aug 2007 14:25:59 GMT

In Japan, recent shifts in the economic environment have increased competition for domestic pharmaceuticals as the larger pharma companies from Europe and the US are afforded more and more of the Japanese market share This background of increased competition led to three notable mergers in fiscal...

Johnson & Johnson: Performance, Products, Pipeline and Potential

press@researchandmarkets.com — Wed, 01 Aug 2007 14:17:53 GMT

Johnson & Johnson operates in nearly all markets worldwide and has developed a substantial infrastructure consisting of over 230 companies active in all fields of healthcare In 2008, J&J achieved record levels of revenue in excess of US$63 billion, with the largest of its three business segments,...

Gilead Sciences: Pipeline - Products - Performance - Potential

press@researchandmarkets.com — Wed, 01 Aug 2007 14:13:22 GMT

In 2006, Gilead took a gamble, believing the short-term costs incurred through the acquisitions of Corus Pharma, Myogen and Raylo Chemicals would lead to long-term growth for the company The consequence of which was, despite record sales, Gilead reported its biggest income losses in recent corporate...

Chugai: Pipeline, Products, Performance and Potential

press@researchandmarkets.com — Wed, 01 Aug 2007 14:08:36 GMT

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Executive Summary

Chugai Pharmaceuticals is a research-driven, pure-play pharmaceutical company, headquartered in Japan. As a member of the Roche Group since October 2002, it has rights to develop and market all pharmaceutical products which the Roche Group decides to commercialise in Japan, and Roche has the right to license-in all Chugai products outside of Japan and South Korea for which Chugai seeks a partner. Chugai maintains all the functions of research, development, production and marketing, as well as retaining management autonomy. The company has now positioned oncology as a key strategic sector along with renal diseases, and bones and joints.

Market conditions in Japan are becoming increasingly fierce. Japan’s medical insurance system is being reformed, with measures being taken to curb medical expenses, including the promotion of generic drug use and the April 2004 national health insurance drug price revisions. In addition, these developments are occurring against a backdrop of rapid demographic change, with a falling birth rate and increasing numbers of aged citizens, and the possibility of further drug price reform.

Now a pure-play prescription pharmaceuticals company, Chugai is well equipped to face these challenges as a

Santarus, Inc. - SWOT Analysis

press@researchandmarkets.com — Fri, 20 Jul 2007 10:12:41 GMT

Our Santarus, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

Santarus is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for patients with gastrointestinal diseases and disorders. The company is headquartered in San Diego, California and employs 338 people as of December 2006. -The company recorded revenues of $94.4 million during the fiscal year ended December 2007, an increase of 91.8% over 2006. The operating loss of the company was $47.3 million during fiscal year 2007, as compared to an operating loss of $59.5 million in 2006. The net loss was $44.3 million in fiscal year 2007, as compared to the net loss of $56.5 million in 2006. -Unaudited results http://phx.corporate-ir.net/phoenix.zhtml?c=175502&p=irol-newsArticle&ID=1114779&highlight=

Scope of the Report

- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement

Reasons to Purchase

- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available

Pharmacoeconomics and Health Outcomes: Driving Formulary Access and Reimbursement

press@researchandmarkets.com — Wed, 23 May 2007 15:49:27 GMT

Examine pharmacoeconomics and health outcomes budgets, structures and strategies: With ever-increasing pressures from managed care organizations, government agencies, pharmacy benefit managers and other reimbursement groups for pharmaceutical companies to prove their products’ value,...

Pharmaceutical Product Relaunch: Preserving Market Share through Line Extension and New Market Entry Strategies

press@researchandmarkets.com — Wed, 23 May 2007 15:26:00 GMT

Uncover the decisions, investments and timing behind successful relaunch strategies: Product teams must begin their relaunch planning early to incorporate it into a strong overall lifecycle management strategy As product teams enter Phase 2 of development for their initial launch, they are often...

Global Cancer Focus Company Directory

press@researchandmarkets.com — Wed, 02 May 2007 15:36:42 GMT

Global Cancer Focus Company Directory pulls out virtually all cancer drug developing companies in the world After several acquisitions and mergers in the market place, we offer you the tool to get an updated look on the competitive landscape in oncology, including almost 900 hundred companies in 39...

Bristol-Myers Squibb: Pharmavitae Profile

press@researchandmarkets.com — Fri, 27 Apr 2007 11:06:20 GMT

This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope of this title:

Highlights of this title:

Reasons to order your copy:
Benchmark BMS performance against key rivals in the ethical pharmaceutical sector Assess the potential loss of US patent exclusivity for key growth driver Plavix from 2007 onwards Evaluate how BMS will diversify its therapeutic focus via new drug launches thereby reducing its dependence on the cardiovascular market

Generic Series: Benchmarking Patent Expiries - Key Factors Affecting Brand Erosion At Patent Expiry

press@researchandmarkets.com — Fri, 27 Apr 2007 11:06:04 GMT

With declining returns from drug development pipelines, preservation of branded revenues is key for manufacturers Inevitably though, once the core product patent of a pharmaceutical drug expires, generic companies will launch their own, cheaper versions of the drug, encouraging product switching and...

Almirall: Pharmavitae Profile

press@researchandmarkets.com — Fri, 27 Apr 2007 11:06:01 GMT

This analysis examines the historical and forecast performance for Almirall in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope of this title:

Highlights of this title:

Reasons to order your copy:
Benchmark Almiralls performance against key rivals in the ethical pharmaceutical sector See how the companys growth prospects will be hampered by the patent expiries of its four key products: Prevencor, Ebastel, Dobupal and Plusvent

Executing Change in the Pharma Industry - Prescription for Pfizer

press@researchandmarkets.com — Wed, 28 Mar 2007 13:53:15 GMT

Pharmaceutical history is littered with the abandoned husks of great ideas, many costing a king’s ransom and never able to live up to their promise Indeed, there is little doubt that in recent years pharmaceutical companies have been getting their execution wrong The key to future survival and...

State of the Pharmaceutical Industry, 2007

press@researchandmarkets.com — Mon, 12 Mar 2007 15:13:43 GMT

“Change is in the air for pharmaceutical companies as governments and judiciary work to strike a balance between ongoing business practices, patent laws, and drug price controls 2007 will almost certainly end with harsher regulatory and legislative environments There has never been a greater need...

Pharmaceutical Companies Performance Tables 2006

press@researchandmarkets.com — Thu, 08 Mar 2007 15:29:13 GMT

This essential business reference report compares and contrasts the performance and fortunes of leading pharmaceutical companies Each company is ranked against a range of key business and financial performance indicators, using reported figures from 2001 to 2005 Who are the winners and losers in the...

Emerging Generic Drug Companies Worldwide 2007

press@researchandmarkets.com — Tue, 06 Mar 2007 17:14:29 GMT

The operating environment for medium-sized generic drug manufacturers is changing rapidly as the industry matures and growth focuses on new market opportunities Consolidation continues to affect companies, as acquisition becomes the instrument of choice in the drive for market share But… -Who are...

Gilead: PharmaVitae Profile

press@researchandmarkets.com — Fri, 02 Feb 2007 14:41:44 GMT

This analysis examines the historical and forecast performance for Gilead in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:
- Benchmark Gileads performance against key rivals in the ethical pharmaceutical sector
- Understand how Gileads growth rate will slow as next generation products cannibalize predecessor product sales

King Pharmaceuticals: PharmaVitae Profile

press@researchandmarkets.com — Tue, 16 Jan 2007 16:38:13 GMT

Introduction

This analysis examines the historical and forecast performance for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Kings performance against key rivals in the ethical pharmaceutical sector See how Kings future depends on the success of its launch portfolio following the patent expiry of several of the companys key products

2006 Industry Dynamics: Lessons to Be Learned

press@researchandmarkets.com — Tue, 02 Jan 2007 14:30:36 GMT

Stunning successes and startling failures highlight 2006’s pharmaceutical industry In this year-end retrospective report, we contemplate the importance of these developments and what they mean to the pharmaceutical industry Additionaly, we asked industry experts for their opinions and integrated...

Clinical Laboratory Testing Market Overview 2006

press@researchandmarkets.com — Thu, 14 Dec 2006 09:57:11 GMT

Clinical laboratory testing is generally categorized as either clinical testing, which is performed on body fluids including blood and urine, or anatomical pathology testing, which is performed on cytologic samples, tissue and other samples, including human cells Clinical and anatomical pathology...

2006 Financings: IPOs and Pharmas Acquisitions of Private (IPO-less) Companies

press@researchandmarkets.com — Wed, 13 Dec 2006 16:13:59 GMT

Private start-up life sciences companies use at least two different financing strategies: sell the whole company to a larger pharmaceutical company or sell shares of the company on a public market While these young companies may feel they are too young to die from an early acquisition, big pharma...

Takeda: PharmaVitae Profile

press@researchandmarkets.com — Tue, 24 Oct 2006 11:42:12 GMT

This analysis examines the historical and forecast performance for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:
-Benchmark Takedas performance against key rivals in the ethical pharmaceutical sector
-Analyze Takedas performance out to 2011 in light of the wave of M&A activity that has swept across the Japanese pharmaceutical market
-Assess whether Takeda can restructure its portfolio to drive long-term growth and counteract forecast declining revenues for its key drug franchises

Mergers, Acquisitions and Licensing to Continue Drive Industry Growth

press@researchandmarkets.com — Tue, 24 Oct 2006 11:42:11 GMT

Inorganic growth strategies have played a significant role in the pharmaceutical industry over recent years. While acquisitions and licensing look set to continue to drive growth in the future, increasing competition for the best deal and best partner will require companies to review a broader set of potential targets and search for earlier stage licensing opportunities

Scope of this title:
-A review of recent "mega-mergers" within the pharmaceutical industry
-Analysis of the leading pharmaceutical companies increased reliance on in-licensed drugs
-A brief analysis of why companies must consider earlier stage licensing opportunities

Highlights of this title:
Large scale "mega-mergers" have shaped the competitive landscape of the leading pharmaceutical players, but analysis suggests that they may not have delivered the expected returns.

In-licensing activity has favored late stage pipeline products in the past, but increasing competition is driving the need for companies to consider early stage deals

Reasons to order your copy:
-Understand the drivers behind the increasing use of small-scale acquisitions and licensing
-Gain insight into the need to focus on earlier stage product licensing to secure the best opportunities

Biologic Drugs to Drive Pharmaceutical Market Growth

press@researchandmarkets.com — Tue, 24 Oct 2006 11:42:11 GMT

As patent expiries take their toll on small molecule blockbuster drugs Big Pharma are turning to biologic therapies to drive future growth. Alliances and partnerships will be a key strategy in gaining access to the technology needed to successfully penetrate this market

Scope of this title:
-An overview of our forecasts for the biologic therapy sales of the leading pharmaceutical companies
-Discussion of the leading Big Pharma players operating in this area
-A review of the evolution in antibody engineering which is currently driving the growth of this area

Highlights of this title:
Biologic therapies will drive the majority of the Big Pharma companies sales growth to 2010, based on our forecasts. Of these therapies monoclonal antibodies will be the key sales drivers.

Reasons to order your copy:
-Benchmark the presence of the Big Pharma companies in the biologics market place
-Assess the key strategies that companies are using to gain access to the necessary technologies

Serono: PharmaVitae Profile

press@researchandmarkets.com — Tue, 24 Oct 2006 11:42:03 GMT

This analysis examines the historical and forecast performance for Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:
-Benchmark Seronos performance against key rivals in the ethical pharmaceutical sector
-Analyze the potential of Seronos product portfolio, present and future, in view of Merck KGaAs recent acquisition of the company
-Learn how Serono will rely heavily on Rebif to drive growth over the forecast period, benefiting from the companys US co-promotion deal with Pfizer

Altana: PharmaVitae Profile

press@researchandmarkets.com — Mon, 09 Oct 2006 13:10:56 GMT

This analysis examines the historical and forecast performance for Altana in the ethical pharmaceutical sector The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs An interactive...

PharmaDeals® Deal Making Spotlight on Novartis

press@researchandmarkets.com — Fri, 05 May 2006 15:00:16 GMT

We have published a series of reports dedicated to assisting companies in business development and deal making in the pharmaceutical & healthcare sectors Published reports include: - Deal Making Spotlight on Pfizer - Deal Making Spotlight on sanofi-aventis - Deal Making Spotlight on GlaxoSmithKline...

PharmaDeals® Deal Making Spotlight on Johnson & Johnson

press@researchandmarkets.com — Fri, 05 May 2006 14:54:13 GMT

PharmaDeals® Deal Making Spotlight on GSK

press@researchandmarkets.com — Fri, 05 May 2006 14:45:32 GMT